Myocardial perfusion imaging agent - FluoroPharma

Drug Profile

Myocardial perfusion imaging agent - FluoroPharma

Alternative Names: BFPET; BFPET (18)F-TPP

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Harvard Medical School; Massachusetts General Hospital
  • Developer FluoroPharma
  • Class Imaging agents; Organophosphorus compounds
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Coronary artery disease

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Coronary artery disease(Diagnosis, In volunteers) in USA (IV, Injection)
  • 06 Jun 2016 Myocardial perfusion imaging agent (BFPET) licensed to Hainan Sinotau Pharmaceutical in China and Canada
  • 25 Sep 2014 Fluoropharma plans a phase II trial for Coronary artery disease (Diagnosis) in the US (NCT02252783)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top